

ASX RELEASE

11th November 2013

FDA ADVISORY PANEL VOTES FAVOURABLY ON THE FIRST OF ITS KIND HYBRID HEARING DEVICE FROM COCHLEAR LIMITED

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced today that an advisory committee to the US Food and Drug Administration (FDA) voted favorably on the Cochlear™ Nucleus® Hybrid™ L24 Cochlear Implant System.

As reported in August, the original PMA had been filed in the USA for a hybrid cochlear implant.

This is a first of its kind system designed for the treatment of adults with severe to profound sensorineural hearing loss in the high frequencies and normal hearing to only mild hearing loss in the low frequencies, often referred to as “ski-slope” hearing loss.

The panel, comprised of leading physicians and researchers, voted in favor of the new Hybrid device based on substantial clinical evidence demonstrating the safety and efficacy of the Nucleus Hybrid System in patients who met the candidacy criteria.

The FDA is not bound by the recommendations of its advisory committees, but will consider the guidance during the final review of the new Hybrid device.

The Nucleus Hybrid System combines the natural hearing via acoustic amplification of low frequencies with the electrical stimulation of a cochlear implant for high frequencies in one device. It is designed to deliver patients superior quality and clarity of sound in even the most difficult hearing situations, especially hearing in noisy environments.

About Cochlear

Cochlear is the global leader in implantable hearing solutions. It has a dedicated global team of more than 2,700 people who deliver the gift of sound to those with hearing loss in over 100 countries. Its vision is to connect people, young and old, to a world of sound by offering life enhancing hearing solutions.

The Cochlear promise of “Hear now. And always” embodies the company’s commitment to providing its recipients with their best possible hearing performance today and for the rest of their lives. For over 30 years Cochlear has helped hundreds of thousands of people either hear for the first time or reconnect them to their families, friends, workplaces and communities.

For more information, visit www.Cochlear.com.

Ends

Company contacts:

Dr Chris Roberts, CEO/President
p: + 61 2 9428 6555

Neville Mitchell, CFO
p: + 61 2 9428 6555

Media contact:

Piers Shervington, Corporate
Communications
P: +61 2 9425 5416